TY - JOUR

T1 - A potent, broadly neutralizing human monoclonal antibody that efficiently protects hACE2-transgenic mice from infection with the Wuhan, BA.5, and XBB.1.5 SARS-CoV-2 variants

AU - Guselnikov, Sergey V.

AU - Baranov, Konstantin O.

AU - Kulemzin, Sergey V.

AU - Belovezhets, Tatyana N.

AU - Chikaev, Anton N.

AU - Murasheva, Svetlana V.

AU - Volkova, Olga Y.

AU - Mechetina, Ludmila V.

AU - Najakshin, Alexander M.

AU - Chikaev, Nikolai A.

AU - Solodkov, Pavel P.

AU - Sergeeva, Maria V.

AU - Smirnov, Alexander V.

AU - Serova, Irina A.

AU - Serov, Oleg L.

AU - Markhaev, Alexander G.

AU - Kononova, Yulia V.

AU - Alekseev, Alexander Y.

AU - Gulyaeva, Marina A.

AU - Danilenko, Daria M.

AU - Battulin, Nariman R.

AU - Shestopalov, Alexander M.

AU - Taranin, Alexander V.

N1 - The author(s) declare financial support was received for the research, authorship, and/or publication of this article. This research was funded by the Ministry of Science and Higher Education of the Russian Federation (Agreement No 075-15-2021-1086, contract No RF—193021X0015, 15.ИП.21.0015).

PY - 2024/8/9

Y1 - 2024/8/9

N2 - The COVID-19 pandemic has uncovered the high genetic variability of the SARS-CoV-2 virus and its ability to evade the immune responses that were induced by earlier viral variants. Only a few monoclonal antibodies that have been reported to date are capable of neutralizing a broad spectrum of SARS-CoV-2 variants. Here, we report the isolation of a new broadly neutralizing human monoclonal antibody, iC1. The antibody was identified through sorting the SARS-CoV-1 RBD-stained individual B cells that were isolated from the blood of a vaccinated donor following a breakthrough infection. In vitro, iC1 potently neutralizes pseudoviruses expressing a wide range of SARS-CoV-2 Spike variants, including those of the XBB sublineage. In an hACE2-transgenic mouse model, iC1 provided effective protection against the Wuhan strain of the virus as well as the BA.5 and XBB.1.5 variants. Therefore, iC1 can be considered as a potential component of the broadly neutralizing antibody cocktails resisting the SARS-CoV-2 mutation escape.

AB - The COVID-19 pandemic has uncovered the high genetic variability of the SARS-CoV-2 virus and its ability to evade the immune responses that were induced by earlier viral variants. Only a few monoclonal antibodies that have been reported to date are capable of neutralizing a broad spectrum of SARS-CoV-2 variants. Here, we report the isolation of a new broadly neutralizing human monoclonal antibody, iC1. The antibody was identified through sorting the SARS-CoV-1 RBD-stained individual B cells that were isolated from the blood of a vaccinated donor following a breakthrough infection. In vitro, iC1 potently neutralizes pseudoviruses expressing a wide range of SARS-CoV-2 Spike variants, including those of the XBB sublineage. In an hACE2-transgenic mouse model, iC1 provided effective protection against the Wuhan strain of the virus as well as the BA.5 and XBB.1.5 variants. Therefore, iC1 can be considered as a potential component of the broadly neutralizing antibody cocktails resisting the SARS-CoV-2 mutation escape.

KW - COVID-19

KW - Omicron

KW - SARS-CoV-1

KW - iC1 antibody

KW - in vivo protection

UR - https://www.scopus.com/record/display.uri?eid=2-s2.0-85200381438&origin=inward&txGid=1b25149c8896911748bf44141650a01d

UR - https://www.webofscience.com/wos/woscc/full-record/WOS:001282648900001

UR - https://www.mendeley.com/catalogue/335b71fa-da14-3156-ac71-406c6ac247e4/

U2 - 10.3389/fimmu.2024.1442160

DO - 10.3389/fimmu.2024.1442160

M3 - Article

C2 - 39100673

VL - 15

JO - Frontiers in Immunology

JF - Frontiers in Immunology

SN - 1664-3224

M1 - 1442160

ER -